Nathalie Auger - Concepedia

Author

Nathalie Auger

Institut Gustave Roussy ORCID

Also Known As

Auger Nathalie, Auger, Nathalie, Elodie Vauleon, N Auger, N. AUGER, N. Auger, Nathalie Auger

157

Publications

5.3K

Citations

H-Index

Concepts

All Affiliations

Institut Gustave Roussy Inserm Université Paris-Saclay Centre National de la Recherche Scientifique Sorbonne Université

About

Nathalie Auger is an author at Institut Gustave Roussy specializing in medicine, pathology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	16	20	1.3K
2	Health Sciences	7	7	340
3	Engineering	3	3	89
4	Natural Sciences	3	3	108
5	Public Health	1	1	15

Nathalie Auger

Publications

4.8K

Citations

H-Index

Page 1

	Year	Citations
High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial Christophe Massard, Stefan Michiels, Charles Ferté, Cancer Discovery	2017	747
A New Model of Patient Tumor-Derived Breast Cancer Xenografts for Preclinical Assays Elisabetta Marangoni, Anne Vincent‐Salomon, Nathalie Auger, Clinical Cancer Research	2007	405
EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients David Planchard, Yohann Loriot, Fabrice André, Annals of Oncology MedicineEgfr-independent MechanismsImmunologyPathologyCancer Genetics	2015	312
Detection of Circulating Tumor Cells Harboring a Unique <i>ALK</i> Rearrangement in <i>ALK</i>-Positive Non–Small-Cell Lung Cancer Emma Pailler, Julien Adam, Amélie Barthelemy, Journal of Clinical Oncology	2013	279
Molecular profiling of patient-derived breast cancer xenografts Fabien Reyal, Charlotte Guyader, Charles Decraene, Breast Cancer Research	2012	188
Clinical effect of molecular methods in sarcoma diagnosis (GENSARC): a prospective, multicentre, observational study Antoîne Italiano, Ilaria Di Mauro, Jocelyn Rapp, The Lancet Oncology Sarcoma DiagnosisMolecular Diagnostic TechniquesSurgical OncologyOncologyMolecular Methods	2016	180
Accumulation of Segmental Alterations Determines Progression in Neuroblastoma Gudrun Schleiermacher, Isabelle Janoueix‐Lerosey, Agnès Ribeiro, Journal of Clinical Oncology	2010	167
Precision medicine for patients with advanced biliary tract cancers: An effective strategy within the prospective MOSCATO-01 trial Loïc Verlingue, David Malka, Adrien Allorant, European Journal of Cancer Effective StrategySurgical OncologyGliomaMedicinePrecision Medicine	2017	163
Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer Gonzalo Recondo, Laura Mezquita, Francesco Facchinetti, Clinical Cancer Research	2019	162
Crizotinib-Resistant <i>ROS1</i> Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for <i>ROS1</i> - and <i>ALK</i> -Rearranged Lung Cancers Francesco Facchinetti, Yohann Loriot, Mei-Shiue Kuo, Clinical Cancer Research	2016	149

Page 1